Scrip is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Is AstraZeneca/Sanofi Library Exchange Open Innovation's Future?

This article was originally published in Scrip

Executive Summary

Taking collaboration to a new level within Big Pharma, AstraZeneca PLC and Sanofi SA have agreed to share 210,000 of their proprietary chemical compounds from their respective libraries in a bid to increase the number of leads for new medicines. No money will change hands, both companies will be free to use the compounds without restriction, and any profits resulting from one of the two's successful development of a drug using the library would not be shared.

Advertisement

Related Content

Sanofi Pasteur, AstraZeneca Link To Develop MEDI8897 Infant RSV Vaccine

Topics

Advertisement
UsernamePublicRestriction

Register

SC063767

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel